Rocio I R Macias

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4668640/publications.pdf

Version: 2024-02-01

129 papers	6,907 citations	93792 39 h-index	75989 78 g-index
131 all docs	131 docs citations	131 times ranked	7922 citing authors

#	Article	IF	Citations
1	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	1.8	119
2	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	1.8	11
3	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologÃa Y HepatologÃa, 2022, 45, 724-734.	0.2	3
4	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut, 2022, , gutjnl-2022-327099.	6.1	11
5	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology, 2021, 73, 2311-2325.	3.6	40
6	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers, 2021, 13, 2358.	1.7	9
7	Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opinion on Investigational Drugs, 2021, 30, 675-679.	1.9	9
8	Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 547-558.	3.7	60
9	REPLY:. Hepatology, 2021, 74, 1129-1131.	3.6	2
10	REPLY:. Hepatology, 2021, 74, 2319-2321.	3.6	1
11	Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy: A Systematic Review and Individual Participant Data Meta-analysis. Obstetrical and Gynecological Survey, 2021, 76, 521-523.	0.2	0
12	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging, 2021, 13, 23416-23434.	1.4	17
13	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine, 2021, 73, 103661.	2.7	31
14	Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. Biochemical Pharmacology, 2020, 171, 113682.	2.0	7
15	Liver and gastrointestinal cancers. , 2020, , 197-250.		1
16	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	2.9	37
17	Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma. Cancers, 2020, 12, 2116.	1.7	35
18	Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers, 2020, 12, 2605.	1.7	21

#	Article	IF	Citations
19	Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 211-214.	0.7	6
20	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1433.	1.7	20
21	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	1.8	63
22	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	8.2	1,155
23	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 2020, 12, 1644.	1.7	38
24	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1663.	1.7	112
25	Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma. Cells, 2020, 9, 498.	1.8	6
26	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165687.	1.8	8
27	Hepatoprotection of Mentha aquatica L., Lavandula dentata L. and Leonurus cardiaca L.. Antioxidants, 2019, 8, 267.	2.2	13
28	SAT-485-European cliolangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer. Journal of Hepatology, 2019, 70, e846-e847.	1.8	1
29	THU-442-Role of drug transporters in the chemoresistance of hepatoblastoma. Journal of Hepatology, 2019, 70, e353.	1.8	0
30	SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e821-e822.	1.8	0
31	Models for Understanding Resistance to Chemotherapy in Liver Cancer. Cancers, 2019, 11, 1677.	1.7	25
32	Cholangiocarcinoma: Stateâ€ofâ€theâ€art knowledge and challenges. Liver International, 2019, 39, 5-6.	1.9	6
33	Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver International, 2019, 39, 108-122.	1.9	89
34	Mechanisms of Anticancer Drug Resistance in Hepatoblastoma. Cancers, 2019, 11, 407.	1.7	36
35	Causes of hOCT1â€Ðependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumorâ€Selective Gene Therapy. Hepatology, 2019, 70, 1246-1261.	3.6	41
36	Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet, The, 2019, 393, 899-909.	6.3	305

#	Article	IF	Citations
37	Association of Adverse Perinatal Outcomes of Intrahepatic Cholestasis of Pregnancy With Biochemical Markers: Results of Aggregate and Individual Patient Data Meta-analyses. Obstetrical and Gynecological Survey, 2019, 74, 388-390.	0.2	6
38	Epigenetic events involved in organic cation transporter 1â€dependent impaired response of hepatocellular carcinoma to sorafenib. British Journal of Pharmacology, 2019, 176, 787-800.	2.7	39
39	Development and characterization of mouse monoclonal antibodies to eight human complement components: Analysis of reactivity with orthologs of nine mammalian genera. Comparative Immunology, Microbiology and Infectious Diseases, 2019, 62, 7-12.	0.7	4
40	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	3.6	112
41	Molecular bases of the poor response of liver cancer to chemotherapy. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 182-192.	0.7	60
42	Chemoresistance and chemosensitization in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1444-1453.	1.8	91
43	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477.	1.8	72
44	Chemoprotective Role of Vitamin C in Liver Diseases. , 2018, , 139-153.		0
45	Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. Journal of Personalized Medicine, 2018, 8, 14.	1.1	31
46	Role of the placenta in serum autotaxin elevation during maternal cholestasis. American Journal of Physiology - Renal Physiology, 2018, 315, G399-G407.	1.6	9
47	Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. Oncotarget, 2018, 9, 28474-28485.	0.8	12
48	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	3.6	218
49	Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland. Scientific Reports, 2017, 7, 7475.	1.6	12
50	Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid. PLoS ONE, 2017, 12, e0176504.	1.1	31
51	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 15846-15857.	0.8	40
52	Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. Oncotarget, 2017, 8, 34617-34629.	0.8	11
53	Molecular Bases of Chemoresistance in Cholangiocarcinoma. Current Drug Targets, 2017, 18, 889-900.	1.0	45
54	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	8.2	964

#	Article	IF	Citations
55	Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 318-334.	0.9	125
56	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Reviews, 2016, 30, 55-64.	2.8	39
57	Bile Acids in Physiology, Pathology and Pharmacology. Current Drug Metabolism, 2015, 17, 4-29.	0.7	131
58	Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the motherâ€placentaâ€foetus trio during cholestasis of pregnancy. British Journal of Clinical Pharmacology, 2015, 79, 316-329.	1.1	42
59	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). Journal of Controlled Release, 2015, 216, 93-102.	4.8	30
60	The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacologica Sinica, 2014, 35, 1-10.	2.8	44
61	Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatology, 2014, 2014, 1-13.	0.9	34
62	Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis. Journal of Molecular Medicine, 2014, 92, 359-372.	1.7	31
63	Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development. Molecular Cancer Research, 2014, 12, 91-100.	1.5	65
64	Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2. European Journal of Nutrition, 2014, 53, 401-412.	1.8	13
65	Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta, 2013, 34, 810-816.	0.7	31
66	Protective effects of phenolic constituents from Cytisus multiflorus, Lamium album L. and Thymus citriodorus on liver cells. Journal of Functional Foods, 2013, 5, 1170-1179.	1.6	34
67	Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology, 2013, 58, 1065-1073.	3.6	124
68	Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs. Current Cancer Drug Targets, 2012, 12, 402-438.	0.8	57
69	Characterization of the Role of ABCG2 as a Bile Acid Transporter in Liver and Placenta. Molecular Pharmacology, 2012, 81, 273-283.	1.0	63
70	Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. Pharmacological Research, 2012, 66, 419-427.	3.1	9
71	No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors. Molecular Pharmaceutics, 2012, 9, 1693-1704.	2.3	73
72	Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. British Journal of Nutrition, 2011, 106, 1814-1825.	1.2	28

#	Article	IF	Citations
73	Further Characterization of the Electrogenicity and pH Sensitivity of the Human Organic Anion-Transporting Polypeptides OATP1B1 and OATP1B3. Molecular Pharmacology, 2011, 79, 596-607.	1.0	39
74	Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicology and Applied Pharmacology, 2009, 239, 21-28.	1.3	16
75	In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicology and Applied Pharmacology, 2009, 239, 13-20.	1.3	15
76	Excretion of biliary compounds during intrauterine life. World Journal of Gastroenterology, 2009, 15, 817.	1.4	55
77	Molecular bases of the fetal liverâ€“placentaâ€“maternal liver excretory pathway for cholephilic compounds. Liver International, 2008, 28, 435-454.	1.9	24
78	460 PROTEIN-INDEPENDENT CYTOSOL-NUCLEUS TRAFFIC OF BILE ACIDS, SUBNUCLEAR COLOCALIZATION WITH FXR AND ROLE OF ABC TRANSPORTERS IN THE HEPATOCYTE NUCLEUS ENVELOPE. Journal of Hepatology, 2008, 48, S175.	1.8	0
79	Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Reviews in Molecular Medicine, 2008, 10, e9.	1.6	80
80	Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes. American Journal of Physiology - Renal Physiology, 2008, 295, G54-G62.	1.6	9
81	Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis. Journal of Lipid Research, 2007, 48, 1362-1370.	2.0	21
82	Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorganic and Medicinal Chemistry, 2007, 15, 2359-2367.	1.4	15
83	Inhibition of the intestinal absorption of bile acids using cationic derivatives: Mechanism and repercussions. Biochemical Pharmacology, 2007, 73, 394-404.	2.0	18
84	Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases. Biochemical Pharmacology, 2007, 73, 1394-1404.	2.0	21
85	Expression in Human Trophoblast and Choriocarcinoma Cell Lines, BeWo, Jeg-3 and JAr of Genes Involved in the Hepatobiliary-like Excretory Function of the Placenta. Placenta, 2007, 28, 107-117.	0.7	102
86	Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3â^'1 and Can 10. Cell and Tissue Research, 2007, 330, 447-460.	1.5	15
87	Cholestasis During Pregnancy: Aetiopathogenesis, Foetal-Maternal Repercussions and Pharmacological Treatments. Current Women's Health Reviews, 2007, 3, 235-247.	0.1	1
88	316 Cotransport of glutathione and bile acids via OATP8/1133. Potential role in the basolateral efflux of cholephilic organic anions from hepatocytes in cholestatic liver diseases. Journal of Hepatology, 2006, 44, S122.	1.8	0
89	Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sciences, 2006, 79, 1014-1019.	2.0	8
90	Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid. Placenta, 2006, 27, 34-41.	0.7	80

#	Article	IF	Citations
91	Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R749-R756.	0.9	11
92	OATP8/1B3-mediated Cotransport of Bile Acids and Glutathione. Journal of Biological Chemistry, 2006, 281, 30326-30335.	1.6	78
93	Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clinical Science, 2005, 109, 199-207.	1.8	13
94	Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an â€œin vitroâ€• replicative system. Antiviral Research, 2005, 68, 75-83.	1.9	198
95	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Annals of Hepatology, 2005, 4, 70-76.	0.6	29
96	Long-Term Effect of Treating Pregnant Rats with Ursodeoxycholic Acid on the Congenital Impairment of Bile Secretion Induced in the Pups by Maternal Cholestasis. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 751-758.	1.3	17
97	Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. Journal of Hepatology, 2005, 43, 324-332.	1.8	68
98	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Annals of Hepatology, 2005, 4, 70-6.	0.6	8
99	72 Maternal cholestasis induces oxidative stress and cell death in rat placenta and foetal liver. Protective effect of ursodeoxycholic acid. Journal of Hepatology, 2004, 40, 26.	1.8	1
100	The Hepatobiliary-like Excretory Function of the Placenta. A Review. Placenta, 2003, 24, 431-438.	0.7	42
101	Excretion of Foetal Bilirubin by the Rat Placentaâ€“Maternal Liver Tandem. Placenta, 2003, 24, 462-472.	0.7	15
102	TNP-470 inhibits oxidative stress, nitric oxide production and nuclear factor kappa B activation in a rat model of hepatocellular carcinoma. Journal of Hepatology, 2003, 38, 98-99.	1.8	65
103	Effect of Ursodeoxycholic Acid on the Impairment Induced by Maternal Cholestasis in the Rat Placenta-Maternal Liver Tandem Excretory Pathway. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 515-524.	1.3	57
104	Usefulness of Liposomes Loaded with Cytostatic Bile Acid Derivatives to Circumvent Chemotherapy Resistance of Enterohepatic Tumors. Molecular Pharmacology, 2003, 63, 742-750.	1.0	40
105	TNP-470 Inhibits Oxidative Stress, Nitric Oxide Production and Nuclear Factor Kappa B Activation in a Rat Model of Hepatocellular Carcinoma. Free Radical Research, 2003, 37, 841-848.	1.5	22
106	Effect of maternal obstructive cholestasis during pregnancy on the biliary transport of horseradish peroxidase in the rat offspring. Clinical Science, 2003, 105, 347-353.	1.8	6
107	Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochemical Journal, 2003, 371, 897-905.	1.7	160
108	Evidence for Dual Effects of DNA-Reactive Bile Acid Derivatives (Bamets) on Hepatitis B Virus Life Cycle in anIn VitroReplicative System. Antiviral Chemistry and Chemotherapy, 2002, 13, 371-380.	0.3	8

#	Article	IF	Citations
109	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587-593.	1.8	48
110	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587.	1.8	25
111	Relationship Between Tumor Cell Load and Sensitivity to the Cytostatic Effect of Two Novel Platinum-bile Acid Complexes, Bamet-D3 and Bamet-UD2. Journal of Drug Targeting, 2002, 10, 397-404.	2.1	7
112	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587-93.	1.8	15
113	Structural characterization and cytostatic activity of chlorobischolylglycinatogold(III). Journal of Inorganic Biochemistry, 2001, 84, 287-292.	1.5	14
114	Overcoming cisplatin resistancein vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2. International Journal of Cancer, 2000, 88, 287-292.	2.3	27
115	Effect of maternal cholestasis on bile acid transfer across the rat placentaâ€“maternal liver tandem. Hepatology, 2000, 31, 975-983.	3.6	53
116	Structural Characterization, Kinetic Studies, and in Vitro Biological Activity of Newcis-Diamminebis-cholylglycinate(O,Oâ€˜) Pt(II) andcis-Diamminebis-ursodeoxycholate(O,Oâ€˜) Pt(II) Complexes. Bioconjugate Chemistry, 2000, 11, 167-174.	1.8	37
117	Overcoming cisplatin resistance in vitro by a free and liposomeâ€encapsulated bile acid derivative: BAMETâ€R2. International Journal of Cancer, 2000, 88, 287-292.	2.3	1
118	Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). Journal of Controlled Release, 1999, 57, 161-169.	4.8	18
119	Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. Journal of Hepatology, 1999, 31, 521-528.	1.8	41
120	DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. International Journal of Cancer, 1998, 78, 346-352.	2.3	27
121	Transient enterohepatic circulation and enhanced biliary versus urinary excretion of the cytostatic drug bischolylglycinate-chloroplatinum(II) (Bamet-H2)1Part of this work has appeared in abstract form in Hepatology (1996) 24:372A:982.1. International Journal of Pharmaceutics, 1998, 172, 79-88.	2.6	3
122	Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II). Journal of Hepatology, 1998, 28, 417-425.	1.8	21
123	Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. Journal of Lipid Research, 1998, 39, 1792-1798.	2.0	22
124	In vitro test to determine the effect of cytostatic drugs on co-cultured rat hepatocytes and hepatoma cells. International Journal of Experimental Pathology, 1998, 79, 109-115.	0.6	4
125	Synthesis and Characterization of the New Cytostatic Complexcis-Diammineplatinum(II)â^'Chlorocholylglycinate. Bioconjugate Chemistry, 1997, 8, 453-458.	1.8	41
126	Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. Hepatology, 1996, 23, 1208-1217.	3.6	42

#	Article	IF	Citations
127	Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. Hepatology, 1996, 23, 1208-1217.	3.6	3
128	Relationship between Bile Acid Transplacental Gradients and Transport across the Fetal-Facing Plasma Membrane of the Human Trophoblast. Pediatric Research, 1995, 38, 156-163.	1.1	32
129	Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International, 0, , .	0.2	0